These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38711136)

  • 41. Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
    Panaro F; Kellil T; Vendrell J; Sega V; Souche R; Piardi T; Leon P; Cassinotto C; Assenat E; Rosso E; Navarro F
    J Surg Oncol; 2019 Sep; 120(3):483-493. PubMed ID: 31197842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer.
    Shin SH; Park Y; Hwang DW; Song KB; Lee JH; Kwon J; Yoo C; Alshammary S; Kim SC
    Anticancer Res; 2019 Feb; 39(2):1005-1012. PubMed ID: 30711988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
    Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
    Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Geriatric Nutritional Risk Index Predicts Tolerability of S-1 as Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
    Sakamoto A; Funamizu N; Shine M; Uraoka M; Nagaoka T; Honjo M; Tamura K; Sakamoto K; Ogawa K; Takada Y
    Pancreas; 2023 Mar; 52(3):e196-e202. PubMed ID: 37824399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
    Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
    World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
    Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma.
    Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
    Anticancer Res; 2021 Mar; 41(3):1629-1639. PubMed ID: 33788759
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas.
    Nakayama Y; Sugimoto M; Gotohda N; Konishi M; Takahashi S
    J Surg Res; 2018 Jan; 221():15-23. PubMed ID: 29229121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
    Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M
    Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
    Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
    Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
    Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
    Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
    [TBL] [Abstract][Full Text] [Related]  

  • 53. National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection.
    Ellis RJ; Ho JW; Schlick CJR; Merkow RP; Bentrem DJ; Bilimoria KY; Yang AD
    Ann Surg Oncol; 2020 Mar; 27(3):909-918. PubMed ID: 31691112
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.
    Adham M; Jaeck D; Le Borgne J; Oussoultzouglou E; Chenard-Neu MP; Mosnier JF; Scoazec JY; Mornex F; Partensky C
    Pancreas; 2008 Nov; 37(4):352-7. PubMed ID: 18665012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
    Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
    BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.
    Hamner JB; White M; Crowder C; Singh G
    World J Surg Oncol; 2015 Sep; 13():290. PubMed ID: 26419361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma.
    Xu X; Wang Y; Chen J; Ma H; Shao Z; Chen H; Jin G
    J Gastrointest Surg; 2012 Aug; 16(8):1493-8. PubMed ID: 22639377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
    Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
    Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
    Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
    Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
    Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
    Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.